

The Quarterly Rx: Q1 2026 U.S. Biopharma Recap

April 2026

William Blair

Q1 2026 U.S. Biopharma Market Summary – Key Takeaways

Biopharma recovery continued in 2026, despite broader geopolitical and macroeconomic uncertainty, as continued robust M&A and positive clinical catalysts lifted the sector

Strong Hop, Softer Drop

- Biopharma carried its Q4 momentum into the start of 2026, with the XBI reaching a $132.09 high in Q1 and ending the quarter up +4.8%, relative to the S&P 500's loss of (4.6%)
- Broader markets moved sharply lower as geopolitical tensions, weaker macro data, and AI-related volatility weighed on sentiment
- Decoupling within healthcare, with XBI outperforming the Healthcare Select Sector Index (XLV)[1] as capital rotates from "defensive" large-cap pharma into high-beta, catalyst-driven biopharma

Tracing the Rabbit: Tracks of Private Capital

- Private markets remained active (62 deals / $5.1 billion raised), though concentrated in fewer, higher-quality asset-focused stories with ~29% of deals raising >$100 million in proceeds
- Asset-NewCos from Asia rose this quarter, with 6 company launches compared to 10 across all of 2025
- Crossover investors remained engaged, signaling a continued reopening of the public/private continuum
- Capital is being increasingly deployed into new opportunities rather than existing portfolio companies; amongst the most active private investors in Q1 2026, ~65% of investments were made into new portfolio companies
- Investor fundraising reached $9.2 billion, much of which driven by Blackstone's oversubscribed $6.3 billion BXLS VI

Spring Awakening: The New Era of Issuance

- Biopharma IPO window reopened (7 pricings / $1.8 billion raised), marking the strongest quarter since Q4 2021
- Secondary activity (FO/PIPE/RDs) remained robust (64 pricings / $10.5 billion raised), putting 2026 on pace to exceed 2025
- Heavily oversubscribed financings and increased generalist participation highlight strong demand to both initiate and scale positions

Cracked Eggs: What Didn't Work?

- Ongoing FDA leadership turnover and growing dissonance between guidance and regulatory actions add to near-term regulatory uncertainty; recent string of approvals for Denali, Corcept, and Rocket represent a constructive, but early, signal for the regulatory environment
- Despite improving sector health, 90 companies are still trading at negative EV and 28% of companies have <1 year of cash
- While the 2026 IPO class is still in the early innings, aftermarket performance has been mixed with 5/7 trading below issue price and the median offer/current down 22%

Basket Building: Big Pharma on the Hunt

- M&A momentum carried into 2026, with 4 deals announced >$5 billion in TDV and 12 deals >$1 billion in TDV, despite several heavily rumored names yet to transact
- Partnering remained active (~$6 billion in upfronts), with 49% of all upfronts driven by large East-West collaborations and 42% of all preclinical collaborations involving AI-enabled platforms
- $330+ billion of large pharma revenue faces LOEs over the next five years, sustaining pressure for M&A and dealmaking

Q1 2026 Golden Eggs

HIGHLIGHTS FROM THE QUARTER

LARGEST M&A DEAL
Arcellx/Gilead - $8.1 billion ($7.8 billion upfront)

LARGEST PARTERNING DEAL
CSPC/AstraZeneca - $18.5 billion ($1.2 billion upfront)

BIGGEST IPO
Generate Bio raising $400.0 million

BIGGEST SECONDARY OFFERING
Xenon raising $747.5 million

MOST IMPACTFUL CLINICAL CATALYST (BY MARKET CAP)
Roivant's Phase II brepocitinib data ($3.3 billion in market cap gained)

(1) XLV is used as a proxy for broad U.S. large-cap healthcare sector performance.

XBI Subsector Market Performance

- After a strong performance in 2025, momentum in the biopharma sector continued into 2026 with the XBI up ~57% over the last twelve months and ~92% from its 52-week low in April 2025
- Small caps outperformed their mid/large cap peers in Q1 2026 as investors shift focus back to riskier assets

Subsector Category		Q1 2026 Performance	LTM Performance	2025 Performance
Market Cap	Small Cap (<$2bn)	12.6%	140.9%	78.9%
	Large Cap (>$10bn)	5.6%	27.4%	15.7%
	Mid Cap ($2-10bn)	2.0%	60.1%	29.0%
Stage of Development	Clinical (N=63)	7.9%	149.2%	71.1%
	Commercial (N=56)	6.3%	37.3%	31.8%
Therapeutic Area	Infectious Disease (N=9)	67.8%	50.7%	63.8%
	Oncology (N=34)	25.5%	162.6%	62.4%
	Liver (All) (N=11)	9.3%	73.3%	40.8%
	Inflammation & Immunology (N=22)	9.0%	100.0%	52.5%
	Rare Disease (N=36)	2.6%	64.1%	35.6%
	Blood (Non-oncology) (N=9)	2.5%	103.0%	67.7%
	Neurology (N=21)	(2.1%)	102.8%	43.3%
	Neuropsych (N=4)	(2.8%)	(1.0%)	(6.8%)
	Pulmonology & Respiratory (N=7)	(7.6%)	39.7%	22.6%
	Musculoskeletal (N=8)	(10.0%)	5.7%	(10.6%)
	MASH (N=5)	(10.1%)	137.3%	92.2%
	Cardiovascular (N=5)	(10.7%)	117.8%	112.2%
	Endocrine (N=3)	(11.6%)	(9.0%)	(21.8%)
	Metabolic (N=5)	(13.1%)	30.7%	29.5%
	Renal (N=4)	(13.4%)	31.9%	30.0%
Modality	I/O (N=10)	40.3%	64.0%	34.7%
	Cell Therapy (N=8)	40.2%	62.5%	41.6%
	Vaccines (N=5)	36.3%	33.2%	(28.2%)
	Precision & Targeted Onc. (N=11)	35.8%	279.2%	73.1%
	Multi-specific Ab's & Engagers (N=6)	12.0%	44.6%	22.6%
	RNA/Oligos (N=11)	7.4%	103.5%	40.1%
	Gene Therapy (N=8)	(13.4%)	46.0%	65.0%

Source: FactSet and William Blair internal reporting. Therapeutic area and modality based on William Blair analysis.
Note: Market capitalizations are as of the first trading day of each graph’s performance period.
Subsector indices are equally weighted and averaged. Includes XBI constituents as of December 31, 2025, and performance as of March 31, 2026. Excludes non-therapeutic focused companies in the XBI.

XBI Subsector Short Interest

Short interest has broadly increased across market caps, therapeutic areas, and modalities, as the sector gained in the latter half of the quarter to close up

Subsector Category		Days to Cover Short Position	Q1 2026 Change in Short Interest
Market Cap	Mid Cap ($2-10bn)	8.3	3.6%
	Large Cap (>$10bn)	5.2	3.5%
	Small Cap (<$2bn)	9.1	3.2%
Stage of Development	Clinical (N=63)	9.2	4.0%
	Commercial (N=56)	6.7	2.8%
Therapeutic Area	MASH (N=5)	6.7	9.1%
	Pulmonology & Respiratory (N=7)	6.9	7.7%
	Infectious Disease (N=9)	7.4	7.4%
	Liver (All) (N=11)	7.9	6.8%
	Blood (Non-oncology) (N=9)	7.2	6.1%
	Endocrine (N=3)	4.1	4.8%
	Neurology (N=21)	7.8	4.5%
	Inflammation & Immunology (N=22)	9.6	3.3%
	Rare Disease (N=36)	7.1	2.7%
	Cardiovascular (N=5)	6.7	2.1%
	Oncology (N=34)	9.2	1.0%
	Musculoskeletal (N=8)	7.0	0.9%
	Neuropsych (N=4)	7.7	(1.0%)
	Metabolic (N=5)	5.6	(1.1%)
	Renal (N=4)	6.9	(10.0%)
Modality	Gene Therapy (N=8)	7.6	10.0%
	I/O (N=10)	9.0	9.7%
	Multi-specific Ab's & Engagers (N=6)	10.1	9.3%
	RNA/Oligos (N=11)	6.9	3.8%
	Cell Therapy (N=8)	8.4	0.2%
	Precision & Targeted Onc. (N=11)	9.5	(1.1%)
	Vaccines (N=5)	9.1	(5.4%)

Source: FactSet, CapIQ, and William Blair internal reporting.
Note: XBI constituents are equally weighted and averaged. Includes XBI constituents as of December 31, 2025.
Excludes non-therapeutic focused companies in the XBI. Market capitalizations are as of the first trading day of the quarter. Days to cover short position calculated as total number of shares shorted / 3-month ADTV. Days to cover short position as of 3/13/26 settlement date. Short interest change measured from 12/31/25 to 3/13/26 settlement dates.

Q1 2026 Biopharma Private Financings Trends

- 62 deals in Q1 2026 have raised total proceeds of $5.1B
- Asset-NewCos sourced out of Asia were more prevalent this quarter, with 6 private company launches compared to 10 in all of 2025

Total Proceeds and Deal Volume

($ in billions)



	2023	2024	2025	2026YTD	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
# of Deals ≥$100M	**62**	**94**	**76**	**18**	**22**	**24**	**24**	**24**	**18**	**15**	**16**	**27**	**18**
% Deals ≥$100M	**26%**	**39%**	**30%**	**29%**	**34%**	**33%**	**47%**	**46%**	**29%**	**31%**	**29%**	**33%**	**29%**

Analysis by Series Round

($ in millions, deal size represents mean, includes extension rounds)

	2024				2025				Q1 2026			
Series Round	**Deal Size**	**Series Count**	**% Ext. Rounds**	**% Clin. Stage**	**Deal Size**	**Series Count**	**% Ext. Rounds**	**% Clin. Stage**	**Deal Size**	**Series Count**	**% Ext. Rounds**	**% Clin. Stage**
Series A	$100	101	16%	33%	$82	109	22%	43%	$70	26	23%	58%
Series B	$87	79	20%	59%	$83	81	21%	72%	$75	26	19%	65%
Series C	$99	39	13%	79%	$92	36	11%	86%	$107	3	0%	33%
Series D+	$128	21	0%	86%	$123	24	8%	92%	$101	7	29%	86%
All Rounds	**$98**	**240**	**15%**	**54%**	**$88**	**250**	**19%**	**63%**	**$82**	**62**	**21%**	**63%**

Q1 2026 Analysis by TA and Stage

Therapeutic Area



Stage of Development



Source: CapIQ, PitchBook Data, Inc., and SEC Filings as of March 31, 2026.
Note: Includes Series A and later private financing deals and extension rounds with a minimum disclosed deal size of $20M, involving at least one U.S./EU healthcare investor.
Ext = Extensions.

Q1 2026 Biopharma Crossover Financings

Q1 2026 marks the third consecutive quarter with more than $1B in crossover proceeds raised, reflecting growing optimism in the IPO window reopening

Q1 2026 Crossovers

($ in millions)

Deal Date	Company	Series	Deal Size	Lead Investors	Days Since Prior Round	Stage	Modality	Therapeutic Area
3/31/26	Ambrosia Biosciences	Series B	$100	Blue Owl; Deep Track Capital; Redmile Group	476	Preclinical	Small Molecule	Metabolic
2/18/26	Korsana Biosciences	Series A	$150	TCGX; Wellington Management	779	Preclinical	Antibody	Neurology
2/5/26	angitia	Series D	$130	Frazier Healthcare Partners; venrock	421	Phase II	Bispecific Antibody	Musculoskeletal
1/22/26	CORXEL	Series D – Extension	$287	ND	490	Phase II	Small Molecule	Metabolic
1/12/26	mirador Therapeutics	Series B	$250	ND	662	Phase II	Small Molecule	I&I, Fibrosis
1/8/26	diagonal Therapeutics	Series B	$125	Janus Henderson Investors; sanofi ventures	645	Preclinical	Bispecific Antibody	Cardiovascular, Pulmonary
1/8/26	Parabilis Medicines	Series F	$305	Fidelity Investments; Janus Henderson Investors; RA Capital	678	Phase I/II	Peptide	Oncology

Total Crossover Volume and Proceeds



	2023	2024	2025	2026YTD	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Median Deal Size	$150	$133	$120	$150	$175	$133	$135	$115	$110	$90	$125	$157	$150
% Clinical	67%	71%	93%	57%	86%	73%	80%	54%	71%	100%	100%	100%	57%

Pre-Crossover-to-Crossover Metrics[1]



	2023	2024	2025	2026YTD	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
# Public	12	12	3	0	4	2	3	3	0	1	1	1	0
# Acquired	6	9	0	0	2	1	3	3	0	0	0	0	0

Source: CapIQ, PitchBook Data, Inc., and SEC Filings as of March 31, 2026.
Note: Includes crossover rounds for companies that have completed an IPO as well as crossover rounds where the next round of financing will likely be an IPO: either a $50M+ raise (Series B onwards) or a $100M+ raise (Series A) with multiple crossover and/or large mutual funds in the syndicate. Lead asset information shown.
(1) Chart reflects median values.

Q1 2026 Most Active Private Biopharma Investors and New Funds Closed

- Investors are deploying capital into new opportunities (vs. existing portfolio); amongst the most active investors in Q1 2026, approximately 65% of investments were in new portfolio companies
- Newly formed life sciences funds raised a total of $9.2B in Q1 2026, led by Blackstone's $6.3 billion BXLS VI

Most Active Private Investors in Q1 2026

Investor	Series A	Series B	Series C	Series D+	% New	% New Δ '25	% Lead
Janus Henderson Investors	4	5		2	91%	↑ 11%	45%
RA Capital Management	2	5		3	80%	↑ 53%	50%
OrbiMed	2	4		1	29%	↓ (10%)	29%
Frazier Life Sciences	3	1		2	83%	↑ 8%	50%
Sanofi / Sanofi Ventures	3	3			100%	↑ 30%	33%
BVF Partners	1	3		1	40%	↑ 7%	0%
SR One Capital Management	4			1	80%	↑ 30%	20%
Atlas Venture	2	2			0%	↓ (13%)	25%
Eli Lilly		4			50%	↓ (39%)	0%
EQT Life Sciences	1	3			75%	↑ 25%	50%
Forbion	2	1	1		50%	↓ (19%)	50%
Foresite Capital Management	2	1		1	75%	↑ 25%	50%
F-Prime Capital	2	2			50%	↑ 30%	25%
Lilly Asia Ventures	1	3			50%	↓ (10%)	50%
Logos Capital		3		1	75%	↓ (5%)	0%
Samsara BioCapital		3		1	50%	↑ 7%	0%

■ Series A ■ Series B ■ Series C ■ Series D+

New Funds Closed in Q1 2026

Investor	Fund Name	Close Date	Location	Fund Size ($M)
Lux	Lux Ventures IX	1/7/2026	New York, NY	$1,500
Servier (moved by you)	Strategic Corporate Venture Fund I	1/8/2026	Suresnes, France	$233
andreessen horowitz	Bio+Healthcare Fund	1/9/2026	Menlo Park, CA	$700
Epidarex Capital	Epidarex Capital IV	1/27/2026	Edinburgh, UK	$145
Santé Ventures	Fund V	2/2/2026	Austin, TX	$330
Blackstone	Blackstone Life Sciences VI	3/30/2026	New York, NY	$6,300
Total Fundraising				**$9.2B**

Source: PitchBook Data, Inc., and internal William Blair research as of March 31, 2026.
Note: Includes private financing deals and extension rounds with a minimum disclosed deal size of $20M, involving at least one U.S./EU healthcare investor. Excludes seed rounds.
Fund formation includes most recent publicly disclosed fund raise over $100M in size for investors/funds focused on US-biopharma investments, including broader healthcare funds with life sciences investment personnel.

Q1 2026 Biopharma IPOs

The biopharma IPO window is showing encouraging signs of reopening, with 7 IPOs pricing in Q1 2026, the highest quarterly activity since Q4 2021; on track for nearly 30 IPOs in 2026, with Kailera publicly on file for an expected April debut

($ in millions)

		At Pricing			Pre-Money				% Change Offer/		Lead Product at Pricing			
Pricing Date	Issuer	Deal Value	Market Cap	Deal Value as % of Market Value	Equity Value	Step-Up	Days from Pre-IPO Financing to IPO	Initial File/Offer vs. Range	1 Day	Current	Phase	Therapeutic Area/Modality	Next Major Catalyst (months)	Key Pre-IPO Investors
2/26/26	Generate:Biomedicines	$400	$2,039	20%	$1,639	0.89x	1,024	In Range	(21%)	(22%)	Phase III	I&I / Antibody	1 to 4	ADIA, ARCH, Fidelity, Flagship, Mirae Asset, Morningside, T. Rowe Price
2/6/26	satellos[1]	$57	$249	23%	$182	NA	NA	NA	+11%	(44%)	Phase II	Neurology / Small molecule	1 to 4	Avidity, Perceptive, Qiming, Soleus
2/5/26	AgomAb Therapeutics	$208	$780	26%	$580	1.32x	468	In Range	(8%)	(34%)	Phase IIa	I&I / Small molecule	5 to 10	Cormorant, EQT Life Sciences, Fidelity, Invus, Redmile
2/5/26	Spyglass Pharma	$173	$533	32%	$361	1.20x	248	In Range	+65%	+62%	Phase III	Ophthalmology / Small molecule	25 to 35	NEA, RA Capital, Samsara, Sands Capital
2/4/26	eikon therapeutics	$381	$972	39%	$591	0.41x	355	In Range	(17%)	(41%)	Phase II/III	Oncology / Small molecule	5 to 11	ADIA, Column Group, EcoR1, Foresite, General Catalyst, Lux, T. Rowe Price, TCGx
2/3/26	Veradermics	$295	$635	46%	$340	1.33x	110	Above	+122%	+271%	Phase III	Dermatology / Small molecule	1 to 4	Aberdeen, Invus, Longitude, Marshall Wace, SR One, Surveyor, Suvretta, Viking
1/8/26	Aktis Oncology	$318	$945	34%	$628	1.18x	465	In Range	+24%	(1%)	Phase Ib	Oncology / Radiopharma	12 to 15	Avidity Partners, Baker Brothers, Blue Owl, EcoR1, Janus Henderson, Mirae Asset, MPM BioImpact, Octagon, RA Capital, RTW, T. Rowe Price, TCGx, Vida Ventures

Deal Volume and Proceeds



Deal Sizing and Valuation



Note: Includes U.S. IPOs only. Excludes best efforts IPOs. Excludes IPOs less than $25 million in gross proceeds. All valuations performed on a basic share count basis. ND = Not Disclosed. NA = Not Applicable.
Charts reflect median values.
Source: CapIQ, Dealogic, FactSet and SEC Filings as of March 31, 2026.
(1) TSX-listed issuer's Nasdaq dual-listing.

Biopharma IPO Aftermarket Performance by Cohort

Biopharma IPO cohorts from 2023–2025 have shown strong post-issue stock performance, driven by improving sentiment and clinical momentum, while the 2026 class (still early) remains largely below issue

IPO Cohort Performance



Note: Includes U.S. IPOs only. Excludes IPOs with less than $25 million in gross proceeds. Includes performance of since acquired companies at their takeout price.
Source: Dealogic and FactSet as of March 31, 2026.

Biopharma Follow-on & Registered Direct Trends

- Strong secondary momentum continued in Q1 2026 with $8.6B raised, putting 2026 on track to surpass recent years
- 40% of deals in Q1 2026 leveraged public marketing, the highest % since Q4 2021 as issuers sought broader investor participation

Deal Volume and Proceeds



Issuers Continue to Leverage Catalysts For Registered Offerings



While Discounts Widen Slightly, Day 1 Performance Remains Strong[1]



Despite the Weaker Market Backdrop, Offerings Are Remaining Above Issue



Source: Dealogic as of March 31, 2026.
Note: Includes fully marketed and confidentially marketed follow-on offerings and registered directs. Excludes offerings with gross proceeds below $20 million. Median pricing and performance includes offerings with warrants.
(1) Represents file/offer for fully marketed follow-on offerings and premium/discount to last trade for confidentially marketed follow-on offerings and registered directs.

Biopharma PIPE Trends

Q1 2026 PIPE activity saw an increase in opportunistic offerings driven by reverse inquiry as investors look to redeploy capital from recent M&A and issuers strengthen balance sheets ahead of upcoming milestones

Deal Volume and Proceeds



Opportunistic Deals Return as Offering Split Trends Toward Historical Averages



PIPE Offerings Performing Well in the Aftermarket



Deal Size Remains In-Line with Recent Quarters



	2023	2024	2025	2026YTD	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
1-Day Issue (1) Price Break	**33%**	**26%**	**28%**	**29%**	**23%**	**36%**	**25%**	**27%**	**33%**	**33%**	**18%**	**31%**	**29%**

Source: Dealogic as of March 31, 2026.
Note: Excludes offerings with gross proceeds below $20 million.
(1) % of offerings where intra-day low fell more than 5.0% below offer price.

Venture Debt in Biopharma

Despite broader market volatility through the first quarter of 2026, venture debt[1] continues to attract companies looking to raise capital with minimal equity dilution

L6M Venture Debt[1] Financings for Public Biopharma Companies

($ in millions)

Date	Company	Available at Close	Total Facility[2]	Interest Rate	LTM at Close[3] Revenue	LTM at Close[3] EBITDA	Market Cap at Close	Debt / Mkt Cap	Facility / Mkt Cap	Phase of Development
03/24/26	Turn Therapeutics	$7	$15	12.25%	$0	($4)	$101	7.0%	14.9%	Phase II
03/17/26	Zenas BioPharma	$75	$250	9.44%	$10	($211)	$1,347	5.6%	18.6%	Phase III
03/02/26	UroGen Pharma	$200	$250	8.25%	$110	($125)	$926	21.6%	27.0%	Marketed
02/24/26	Beam Therapeutics	$100	$400	10.19%	$140	($361)	$3,207	3.1%	12.5%	Pivotal Phase I / II
02/04/26	Maze	$40	$150	7.95%	$0	($132)	$2,316	1.7%	6.5%	Phase II
01/13/26	Pelthos Therapeutics	$30	$50	10.50%	$7	($21)	$78	38.5%	64.2%	Marketed
01/08/26	Spruce Biosciences	$15	$40	12.25%	$0	($29)	$79	19.0%	50.7%	Filing Ready
12/16/25	Humacyte	$40	$53	11.50%	$2	($97)	$210	19.1%	25.0%	Marketed
11/24/25	Moderna	$600	$1,500	9.16%	$2,232	($3,255)	$9,436	6.4%	15.9%	Marketed
11/03/25	Kyverna	$40	$100	8.75%	$0	($170)	$298	13.4%	33.6%	Pivotal Phase II
10/14/25	Candel Therapeutics	$50	$100	9.75%	$0	($39)	$317	15.8%	31.5%	Phase III Complete
10/06/25	Valneva	$215	$215	9.00%	$211	($68)	$979	22.0%	22.0%	Marketed
Mean		**$118**	**$260**	**9.92%**	**$226**	**($376)**	**$1,608**	**14.4%**	**26.9%**	
Median		**$45**	**$125**	**9.60%**	**$4**	**($111)**	**$621**	**14.6%**	**23.5%**	
Minimum		**$7**	**$15**	**7.95%**	**$0**	**($3,255)**	**$78**	**1.7%**	**6.5%**	
Maximum		**$600**	**$1,500**	**12.25%**	**$2,232**	**($4)**	**$9,436**	**38.5%**	**64.2%**	

Market Overview

- Following another active year in 2025, venture debt continues to be an attractive option for companies looking to raise capital
- Venture debt offers a path for borrowers to extend their runway with minimally dilutive capital and achieve a higher certainty of close, among other benefits
- Additionally, recent downward pressure on interest rates has contributed to lower borrowing costs, reducing cashflow burden
- High-quality borrowers have benefited from attractive structures and terms due to an increasingly competitive market as more lenders enter the space
- With lenders aggressively targeting larger opportunities, average deal sizes have continued to increase
- Bigger deal sizes have been supported by the proliferation of private credit lenders, which have raised increasingly large funds dedicated to investing in venture debt opportunities
- However, lenders are patiently picking their spots to deploy capital, prioritizing high-quality companies

Borrower Traits That Lenders Look For

- ✓ Funding requirement is modest relative to valuation
- ✓ Approved products and / or multiple products in pipeline
- ✓ **Strong investor base and / or material cash equity invested in the business**

Source: CapIQ, PitchBook Data, Inc., and SEC filings as of March 31, 2026.
(1) "Venture debt" defined here as debt to borrowers who do not yet have positive cash flow.
(2) Includes undrawn revolvers and additional tranches of debt / delayed draw facilities that are fully committed at the time of close.
(3) LTM financials at time of close are as calculated by CapIQ.

Strategic Alternatives Outcomes

Reverse merger activity has picked up with 5 deals announced since November 2025 alongside concurrent PIPE financings (median raise of $200M); across these transaction, the public shells had a median net cash balance of $25M

Indicates biopharma companies that have announced a cryptocurrency treasury strategy

2025-2026YTD Strategic Alternatives Outcomes

Outcome Type	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Total
Reverse Merger Traditional reverse mergers with private companies	Salarius Pharmaceuticals / Decoy Therapeutics	Carisma Therapeutics / OrthoCellix	Barinthus Biotherapeutics / Clywedog Therapeutics	Galecto / Damora Therapeutics Vyne Therapeutics / Yarrow	Sensei Bio / Faeth Rallybio / Candid Therapeutics Pulmatrix / Eos Senolytix	8 Deals
Other Strategic Outcomes Includes program or full company buyouts, strategic mergers, cryptocurrency treasury strategy announcements, and/or in-licensings	Acelyrin / Alumis	Eyenovic Vor / RemeGen	180 Life Sciences, Artelo Biosciences, Equillium, Liminatus Pharma, Lixte, MEI Pharma, Portage, Silo Pharma, Sonnet BioTherapeutics, Windtree Therapeutics Adaptimmune / US WorldMeds	Enlivex, Enveric Biosciences, Leap Therapeutics, Propanc Biopharma, Tharimmune Applied Therapeutics / Cycle Pharma Tempest Therapeutics / Factor Bioscience Q32 Bio / Akebia Therapeutics	Kezar Life Sciences / Aurinia	7 Deals / 16 Crypto Strategies
Financially-Driven Take Private Acquisitions Cash acquisition of companies for existing capital on hand and/or royalty rights following strategic review		Allakos, Elevation Oncology, Kronos Bio / Concentra Turnstone Biologics / XOMA	Cargo Therapeutics, IGM Biosciences, iTeos Therapeutics / Concentra LAVA Therapeutics, Mural Oncology, HilleVax / XOMA ESSA / XENO Therapeutics	Repare Therapeutics / XENO Therapeutics Generation Bio / XOMA		13 Deals
Return of Capital Excess cash return to shareholders through dividend, often including concurrent liquidation		Keros Therapeutics (1) Third Harmonic Bio				2 Co.'s
Chapter 11 / Closure Voluntary delisting/ liquidation/bankruptcy *These companies did not have excess cash to distribute to shareholders at closure*	Omega Therapeutics Syros Viracta	Affimed Vincerx Pharma		Carisma Therapeutics	Lipella Pharmaceuticals Lyra Therapeutics iO Biotech Iterum Therapeutics	10 Co.'s
# of Outcomes	5	11	19	13	8	56

Source: SEC Filings, Company Press Releases, and William Blair analysis as of March 31, 2026.
(1) Keros plans to return $375M in capital to existing shareholders and continue operations and development of KER-065.

Q1 2026 SMID-cap Clinical Catalysts Analysis

- Robust catalyst-driven financing quarter with 8 of the top 10 movers raising over $2.6 billion in proceeds
- 4 of the top positive movers were for first and best-in-class derm targets in atopic derm and plaque psoriasis
- Largest decliners typically driven by negative Phase III data/updates; this quarter, 4 of the top decliners were for "positive" catalysts that fell short of investor expectations

Key Takeaways

- William Blair analyzed 73 key clinical data readouts in Q1 2026 for U.S.-listed SMID-cap biopharma companies
- Average stock price performance for "positive" clinical data (N=61):
  - 1-day performance: **+8.2%**
  - 1-week performance: **+9.4%**
- Average stock price performance for "negative" clinical data (N=12):
  - 1-day performance: **(44.3%)**
  - 1-week performance: **(46.1%)**
- ~$11.1B in cumulative 1-day market cap **gained** across all SMID-cap clinical catalysts driven by positive mid/late-stage readouts from Roivant/Priovant, United, Xenon, Insmed and Kodiak, each gaining >$1B in 1-day market cap
- 23 Phase III readouts in Q1 2026, of which 14 were positive and 9 were negative

Breakdown by Therapeutic Area



Oncology, Immunology, Rare Disease, Neurology, Ophthalmology, Metabolic, Other

Top 10 Positive/Negative Movers

(1-Day Share Price Change)

Top Performers

Ticker	1-Day Change	Catalyst Type
CRVS	166%	Phase I Data
ALMS	95%	Phase III Data
KOD	75%	Phase III Data
EVMN	71%	Phase IIa Data
RLMD	61%	Interim Phase II Data
NKTR	51%	Phase IIb Data
ELVN	50%	Interim Phase Ib Data
XENE	50%	Phase III Data
GLUE	45%	Interim Phase I Data
CTMX	44%	Phase I Data

Worst Performers

Ticker	1-Day Change	Catalyst Type
TIL	(46%)	Lead Program Discontinuation
UPB	(47%)	Phase II Data
WVE	(50%)	Interim Phase I Data
ZBIO	(52%)	Phase III Data
AARD	(56%)	Phase III Trial Pause
PEPG	(59%)	Interim Phase II Data
CALC	(76%)	Lead Program Discontinuation
GOSS	(80%)	Phase III Data
IMMP	(82%)	Phase III Data
QNCX	(92%)	Phase III Data

Executed Equity Offering Concurrent with or Post-Data

Source: FactSet, Company press releases, SEC Filings and William Blair analysis as of March 31, 2026.
Note: Includes biopharma companies listed on major U.S. exchanges with market capitalization >$25M and <$30B at the time of catalyst. Positive/negative based on Company press releases.

Q1 2026 Positive/Negative Clinical Catalyst Performance Detail

- 30% of positive clinical catalysts had a >20% one-day stock price movement, while 67% of negative clinical catalysts experienced a one-day price decline greater than 20%
- Q1 2026 clinical catalysts generated a net ~$11.1B increase in 1-day market capitalization

Performance Following a Positive Clinical Catalyst

(1-Day Share Price Change, N = 61; $ values shown after company names indicate 1-Day Market Cap Change)



Performance Following a Negative Clinical Catalyst

(1-Day Share Price Change, N = 12; $ values shown after company names indicate 1-Day Market Cap Change)



Source: FactSet, Company press releases, SEC Filings and William Blair analysis as of March 31, 2026.
Note: Includes biopharma companies listed on major U.S. exchanges with market capitalization >$25M and <$30B at the time of catalyst. Positive/negative based on Company press releases.

Q1 2026 Biopharma M&A Recap

- 20 deals announced for ~$50B in total deal value in Q1 2026, putting 2026 on pace for the strongest M&A year since 2019
- Large public M&A maintained momentum, with four $5B+ deals announced and continued M&A activity expected

Total Deal Value & Volume



Key Takeaways

- Median deal terms for Q1 2026 M&A activity:
  - **Total Deal Value:** $1,613M in Q1 2026 (vs. $820M in 2025)
  - **Upfront (Cash + Equity):** $1,200M in Q1 2026 (vs. $425M in 2025)
  - **Milestones:** $500M in Q1 2026 (vs. $194M in 2025)
- Continued strong pace of private company M&A, with 12 deals announced, well above the ~7 per quarter average across 2025
- Public company M&A volume remained elevated this quarter, with four >$5B+ acquisitions announced, compared to eight >$5B+ deals in 2025 and none in 2024
  - Largest M&A deal this quarter was Gilead's up to $8.1B takeout of long-term partner, Arcellx, at a 79% premium ahead of their upcoming PDUFA date in December 2026
- Therapeutic area interest in Q1 2026 skewed toward I&I (N=7) and oncology (N=6)
- *in vivo* cell therapy remains a large pharma priority, highlighted by Lilly's $2.4B acquisition of Orna: the fifth deal in the space since March 2025
- Focus remains on de-risked assets, with ~2/3 of activity concentrated in Phase I/II or later assets, underscoring the need to offset upcoming LOEs and patent cliffs

Q1 2026 M&A Activity Detail[1]

($ in millions)

Public Company Transactions

Date	Target	Acquiror	Total Deal Value	Total Upfront	Total Earnouts	Premium to Last Unaffected Date	Phase	Therapeutic Area	Modality
3/31/26	Apellis	Biogen	$6,146	$5,600	$546	140%	Marketed	Ophthalmology, Rare Disease	Peptide
3/31/26	Centessa	Lilly	$7,800	$6,300	$1,500	38%	Phase IIa	Neurology	Small Molecule
3/25/26	terns	Merck	$6,700	$6,700	-	6%	Phase I/II	Oncology	Small Molecule
3/6/26	Day One	Servier	$2,500	$2,500	-	68%	Marketed	Oncology, Rare Disease	Small Molecule
2/23/26	Arcellx	Gilead	$8,139	$7,800	$339	79%	Filed	Oncology	Cell Therapy
1/20/26	RAPT	GSK	$2,200	$2,200	-	65%	Phase IIb	I&I	Antibody
1/7/26	ventyx	Lilly	$1,200	$1,200	-	79%	Phase II	I&I	Small Molecule

Private Company Transactions

Date	Target	Acquiror	Total Deal Value	Total Upfront	Total Earnouts	Phase	Therapeutic Area	Modality
3/27/26	Excellergy	Novartis	$2,000	ND	ND	Phase I	I&I	Trifunctional Antibody
3/27/26	transcend	Otsuka	$1,225	$700	$525	Phase III	Neurology	Small Molecule
3/23/26	Ouro Medicines	Gilead	$2,175	$1,675	$500	Phase Ib	I&I	Bispecific Antibody
3/20/26	Synnovation Therapeutics (PI3Kα Inhibitors)	Novartis	$3,000	$2,000	$1,000	Phase I/II	Oncology	Small Molecule
3/19/26	Corium (AZSTARYS)	Collegium	$785	$650	$135	Marketed	Neurology, Spec Pharma	Small Molecule
2/26/26	aicuris	Asahi Kasei	$919	$919	-	Marketed	Infectious Disease, Spec Pharma	Small Molecule
2/25/26	35Pharma	GSK	$950	$950	-	Phase Ib	Cardiovascular	Fusion Protein
2/9/26	ORNA	Lilly	$2,400	ND	ND	Preclinical	I&I	*in vivo* Cell Therapy
1/6/26	Dark Blue Therapeutics	Amgen	$840	ND	ND	Preclinical	Oncology	Small Molecule Protein Degrader

Source: PitchBook Data, Inc., Company press releases and websites as of March 31, 2026.
Note: M&A activity includes biopharma deals with disclosed total deal value of $20M+. Premiums based on upfront offer price, excluding CVRs and milestones, to last close before deal announcement. NA = Not Applicable. ND = Not Disclosed.
(1) Includes M&A with disclosed total deal value of $500M+.

Summary of Investor Capital Returned from Q1 2026 Public Biopharma Acquisitions

Public biopharma acquisitions announced in Q1 2026 freed up an estimated $28 billion in institutional investor capital

($ in millions)

#	Institution	Total Estimated Capital Returned to Fund(1)	Apellis	ARCELLX	CENTESSA	Day One	RAPT	terns	ventyx
1	Avoro Capital Advisor LLC	$1,284.8	✓		✓			✓	
2	Adage Capital Management LP	$744.1		✓	✓	✓	✓	✓	✓
3	Paradigm BioCapital Advisors LP	$701.2		✓				✓	
4	Vestal Point Capital LP	$686.7	✓	✓	✓	✓		✓	✓
5	Fidelity Management & Research Co. LLC	$599.5	✓	✓	✓	✓	✓	✓	✓
6	Wellington Management Co. LLP	$567.8	✓	✓	✓	✓	✓	✓	✓
7	RTW Investments LP	$477.3	✓		✓		✓		✓
8	Deep Track Capital LP	$440.9	✓	✓	✓		✓	✓	
9	Janus Henderson Investors US LLC	$438.3	✓	✓	✓	✓	✓	✓	✓
10	Citadel Advisors LLC	$380.2	✓	✓	✓	✓	✓	✓	✓
11	T. Rowe Price Associates, Inc.	$377.1	✓	✓	✓	✓	✓	✓	✓
12	NEA Management Co. LLC	$350.2		✓					
13	Perceptive Advisors LLC	$327.4	✓	✓	✓		✓	✓	
14	TCG Crossover Management LLC	$317.1			✓		✓		✓
15	T. Rowe Price Investment Management	$305.3	✓	✓	✓		✓		✓
16	Vivo Capital LLC	$283.4		✓				✓	✓
17	Access Industries, Inc.	$278.0				✓			
18	SR One Capital Management LP	$269.9		✓					
19	Glazer Capital LLC	$269.2				✓	✓		✓
20	UBS Securities LLC	$245.9	✓	✓	✓	✓	✓	✓	✓
21	Farallon Capital Management LLC	$238.8	✓	✓	✓			✓	✓
22	Franklin Advisers, Inc.	$237.5	✓	✓	✓	✓		✓	✓
23	The Invus Group LLC	$232.8			✓		✓	✓	
24	General Atlantic LLC	$232.5			✓				
25	Millennium Management LLC	$212.3	✓	✓	✓	✓	✓	✓	✓
26	OrbiMed Advisors	$209.4					✓	✓	✓
27	Pictet Asset Management SA	$203.3	✓	✓	✓	✓		✓	✓
28	Woodline Partners LP	$202.1	✓	✓	✓	✓	✓	✓	✓
29	JPMorgan Investment Management, Inc.	$199.1	✓	✓		✓	✓	✓	✓
30	Lord, Abbett & Co. LLC	$195.5	✓	✓	✓	✓		✓	✓

Source: FactSet and William Blair Analysis as of March 31, 2026.

Note: Excludes index funds, quant/systematic funds, private brokerages, retail, strategic investors, and non-filers. $ value position calculated based on Q4 2025 publicly disclosed institutional ownership of target company multiplied by announced per share acquisition price, excluding contingencies. Includes deals >$1B in upfront cash.

(1) Total estimated capital in millions returned to fund based on the cumulative $ value position of all target companies for shareholders.

Q1 2026 Biopharma Partnership Trends

- Licensing and collaboration TDV soars to multi-year highs, with $81B TDV across 57 partnerships in Q1 2026
- Eli Lilly remains the most active strategic, striking seven deals in Q1 2026 across therapeutic areas representing ~$17B in TDV

Total Deal Value and Volume



Breakdown of Deals in Q1 2026



Most Active Partners in Q1 2026

($ in millions)



Partner	# Deals	Median TDV	Median Upfront
Lilly	7	$1,640	$100
Boehringer Ingelheim	3	$1,733	$100
Novartis	3	$500	$50
sanofi	3	$1,530	$160
abbvie	1	$5,600	$650
astellas	1	$1,705	$335
AstraZeneca	1	$18,500	$1,200
Bristol Myers Squibb	1	$850	$50
Roche	1	$1,700	$200
Gilead	1	$1,535	$85
novo nordisk	1	$2,100	NA

Key Takeaways

Licensing (N=28)

- Median deal terms for licensing agreements in Q1 2026:
  - **Total Deal Value:** $618M in Q1 2026 (vs. $970M in 2025)
  - **Upfront (Cash+Equity):** $50M in Q1 2026 (vs. $53M in 2025)
  - **Milestones:** $963M in Q1 2026 (vs. $990M in 2025)
- 64% of all licensing agreement involved large pharma licensors, up from 40% in 2025
- 36% of licensing agreements focused on clinical-stage assets, compared to 56% in 2025

Collaborations (N=29)

- Median deal terms for collaborations in Q1 2026:
  - **Total Deal Value:** $1,248M in Q1 2026 (vs. $1,007M in 2025)
  - **Upfront (Cash+Equity):** $65M in Q1 2026 (vs. $75M in 2025)
  - **Milestones:** $1,215M in Q1 2026 (vs. $1,000M in 2025)
- Antibodies (including bispecifics and multispecifics) were the most popular modality for collaborations, involved in 31% of agreements, up from 21% in 2025
- 42% of all partnerships were preclinical collaborations, nearly half of which involved AI-enabled platforms

Top 5 Partnerships by Total Upfront in Q1 2026

Chinese Licensor

($ in millions)

Date	Licensor	Licensee	Total Deal Value	Total Upfront	Milestones	Phase	Therapeutic Area	Modality	Target(s)
1/30/2026	CSPC	AstraZeneca	$18,500	$1,200	$17,300	Preclinical	Metabolic	Peptide	GLP-1/GIP
3/31/2026	Gilead	Galápagos	ND	$838	ND	Phase I/II	I&I	Bispecific Antibody	BCMA x CD3
1/12/2026	RemeGen	abbvie	$5,600	$650	$4,950	Phase II	Oncology	Bispecific Antibody	PD-1 x VEGF
2/8/2026	Innovent	Lilly	$8,850	$350	$8,500	Discovery	Oncology, I&I	Antibody	ND
2/23/2026	VIR	astellas	$1,705	$315	$1,390	Phase I	Oncology	Bispecific Antibody	PSMAxCD3

Source: Company press releases and SEC filings as of March 31, 2026.
Note: Excludes regional partnerships, partnerships with undisclosed deal terms, and partnerships with deal terms less than $20M. Early-stage partnerships defined as Phase I or earlier.
Upfront includes near-term milestones. TDV = Total Deal Value.

Asia's Growing Role as an Important Innovation Engine for the West

$2.8 billion in upfront payments went to Asia-headquartered licensors in Q1 2026 to bring assets and development programs to the West, marking the first quarter in which nearly half of all upfront spent on partnering flowed to Asia

32% of Pharma and SMID-Cap Partnering with Asia[1]



Meaningful Growth in Upfront to Asian Licensors



Q1 2026 Activity with Asian Licensors[2]

Top Asset-Focused Large Pharma Partnerships

- **1/12/26** — RemeGen / AbbVie — $5,600M *($650M Upfront)* — BsAb — Phase II — Target: PD-1xVEGF
- **3/4/26** — Sino Biopharmaceutical Limited (中國生物制藥有限公司) / Sanofi — $1,590M *($135M Upfront)* — Small Molecule — Phase II — Targets: JAKxROK
- **2/24/26** — Harbour BioMed / Solstice Oncology — $1,205M *($100M Upfront)* — Antibody — Phase II — Target: CTLA-4
- **2/16/26** — GenHouse (劲浩医药) / Gilead — $1,530M *($85M Upfront)* — Small Molecule — Preclinical — Target: MAT2A
- **2/24/26** — Antengene / UCB — $1,180M *($60M Upfront)* — BsAb — Preclinical — Target: CD19xCD3
- **1/12/26** — PepLib / Novartis — Total Deal Value ND *($50M Upfront)* — Peptide — Preclinical — Targets: ND

Top Discovery-Stage Platform Collaborations

- **1/30/26** — CSPC / AstraZeneca — $18,500M *($1,200M Upfront)* — Peptide — Multi-Target
- **2/8/26** — Innovent / Lilly — $8,850M *($350M Upfront)* — Antibody — Multi-Target
- **2/11/26** — Ribocure Pharmaceuticals AB / Madrigal Pharmaceuticals — $4,400M *($60M Upfront)* — siRNA — Multi-Target

New Company Formations

- **1/9/26** — Haisco / AirNexis Therapeutics — $200M *(Series A)* — Small Molecule — Phase II — Target: PDE3/4
- **1/8/26** — GMAX Bio / Alveus Therapeutics — $160M *(Series A)* — Fusion Protein — Phase II Ready — Target: GIPRxGLP-1
- **2/24/26** — DART Bio / Slate Medicines — $130M *(Series A)* — Antibody — Phase I Ready — Target: PACAP
- **1/14/26** — Qyuns / Caldera Therapeutics — $113M *(Series A and A1)* — BsAb — Phase I — Target: IL-23xTL1A
- **3/17/26** — Alebund / R1 Therapeutics — $78M *(Series A)* — Small Molecule — Phase IIb Ready — Target: MPTs
- **3/3/26** — 康诺亚 (Keymed Biosciences) / Prolium — $50M *(Series A)* — BsAb — Phase I/II Ready — Target: CD20xCD3

Source: Company press releases and SEC filings as of March 31, 2026.
Note: Excludes partnerships in which Daiichi-Sankyo, Otsuka, and Takeda are licensors. Excludes partnerships with undisclosed financials or total financials below $20M. TDV = Total Deal Value. ND = Not Disclosed.
(1) Includes partnerships for assets and development programs involving an Asia-headquartered licensor and ex-Asia licensee covering regions WW or US ex-Asia.
(2) Asset-focused partnerships ordered by upfront size. Discovery-stage platform collaborations ordered by total deal value. New company formations ordered by total deal size.

FDA Approval and First-Time Launcher (FTL) Trends

Against a backdrop of senior-level turnover at the FDA and the announcement of Dr. Vinay Prasad's departure, the recent string of approvals for Denali, Corcept, and Rocket in the last two weeks of March signal stability returning to the regulatory environment

FDA Approvals by Quarter



Select Upcoming Q2/Q3 2026 SMID-cap PDUFA Dates

Resubmission following CRL

Company	Product	Indication	Modality	PDUFA Date
Replimmune	RP1	Advanced melanoma	Gene Therapy	4/10/2026
Grace	GTx-104	Aneurysmal subarachnoid hemorrhage	Small Molecule	4/23/2026
Cingulate	CTx-1301	ADHD	Small Molecule	5/31/2026
Arvinas	Vepdegestrant	ER+/HER2- ESR1-mutated breast cancer	Small Molecule	6/5/2026
Camurus	Oclaiz	Acromegaly	Peptide	6/10/2026
Achieve	Cytisinicline	Smoking cessation	Small Molecule	6/20/2026
Unicycive	Oxylanthanum Carbonate	Hyperphosphatemia in CKD	Small Molecule	6/29/2026
Viridian	Veligrotug	Thyroid Eye Disease	Antibody	6/30/2026
Vera	Atacicept	IgA nephropathy	Fusion Protein	7/7/2026
Celcuity	Gedatolisib	HR+/HER2−/PIK3CA-WT advanced breast cancer	Small Molecule	7/17/2026
Moderna	mRNA-1010	Influenza	Vaccine	8/5/2026
Savara	MOLBREEVI	Autoimmune pulmonary alveolar proteinosis	Recombinant Protein	8/22/2026
Capricor	Deramiocel	DMD cardiomyopathy	Cell Therapy	8/22/2026
Ultragenyx	DTX-401	Glycogen storage disease type 1a	Gene Therapy	8/23/2026
Nuvalent	Zidesamtinib	ROS1+ NSCLC	Small Molecule	9/18/2026
Ionis	Zilganersen	Alexander disease	Antisense Oligo	9/22/2026
Praxis	Relutrigine	SCN2A and SCN8A DEE	Small Molecule	9/27/2026

Q1 2026 SMID-cap PDUFA Outcomes

Approval CRL

Company	Product	Indication	Modality	Outcome	Outcome Date	Evaluating Body[1]
Atara	Ebvallo	EBV+ PTLD	Cell Therapy	Complete Response Letter	1/12/2026	B
Sentynl	Zycubo	Menkes Disease	Gene Therapy	Approved	1/12/2026	B
Tenpoint	Yuvezzi	Presbyopia	Small Molecule	Approved	1/28/2026	D
Aquestive	AQST-109	Type 1 allergic reactions	Small Molecule	Complete Response Letter	2/2/2026	D
Regenxbio	RGX-121	MPS II	Gene Therapy	Complete Response Letter	2/7/2026	B
Acrotech	Adquey	Atopic dermatitis	Small Molecule	Approved	2/12/2026	D
Disc	Bitopertin	Erythropoietic protoporphyria	Small Molecule	Complete Response Letter	2/13/2026	D
Vanda	Bysanti	Schizophrenia, bipolar I disorder	Small Molecule	Approved	2/20/2026	D
Immedica	Loargys	ARG1-Deficiency	Enzyme Replacement	Approved	2/23/2026	D
Eton	Desmoda	AVP-Deficiency	Peptide	Approved	2/25/2026	D
Ascendis	Yuviwel	Achondroplasia	Peptide	Approved	3/2/2026	D
Alderya	Reproxalap	Dry eye disease	Small Molecule	Complete Response Letter	3/2/2026	D
Denali	Avlayah	Hunter syndrome	Enzyme replacement	Approved	3/25/2026	D
Corcept	Lifyorli	Platinum-resistant ovarian cancer	Small Molecule	Approved	3/25/2026	D
Rocket	Kresaldi	Severe LAD-I	Gene Therapy	Approved	3/27/2026	B

LTM SMID-cap PDUFA Outcome Trends

Approval CRL

FDA decisions have been marked by a disproportionally high number of CRLs for candidates evaluated by CBER



Source: FDA.gov, Company press releases, SEC Filings, FactSet, and William Blair analysis as of March 31, 2026.
Note: PDUFA dates exclude label extensions, supplemental applications, and only include PDUFAs of NCEs/NMEs that are submitted via BLA/NDA (excluding diagnostics, biosimilars, generics, source plasma and 505b2s without clinical trial data).
(1) **D** = CDER Evaluation. **B** = CBER Evaluation.

Large Pharma Patent Expirations and Loss of Exclusivity

- An estimated $330B+ of large pharma revenue expected to be impacted from LOEs over the next 5 years
- The largest five upcoming LOEs by value are semaglutide (Ozempic/Wegovy), Keytruda, Dupixent, Eliquis, and Darzalex

Value of Drug LOEs by Year (2026 – 2031)

Represents 2025 Sales ($ in billions)



Total:	13	15	20	19	10	22

Large Pharma LOE Exposure and Deal Activity

($ in billions) LOE Year: ■ = 2026 ■ = 2027 - 2030 ■ = 2031

Company	LOE Value (2025 Sales)	2025-2026YTD Share Price Appreciation	2025-2026YTD Aggregate Upfront Payment[1]	2025-2026YTD Recent Notable Deals
Merck	$40.6	↑ 21%	$26.1	Verona Pharma, Cidara Therapeutics, Terns
Novo Nordisk	$34.6	↓ (59%)	$5.8	akero
Bristol Myers Squibb	$29.2	↑ 7%	$3.8	Orbital, 2seventybio
Johnson&Johnson	$27.3	↑ 70%	$17.7	Intra-Cellular Therapies, Halda Therapeutics
Pfizer	$23.9	↑ 6%	$9.2	Metsera
GSK	$22.2	↑ 62%	$6.2	RAPT, Boston Pharmaceuticals, IDRx
AstraZeneca	$22.0	↑ 47%	$2.4	EsoBiotec, sixpeaks
Novartis	$21.5	↑ 55%	$18.2	Avidity Biosciences, Synnovation Therapeutics, Tourmaline
Roche	$21.3	↑ 40%	$4.4	89bio
Lilly	$14.5	↑ 18%	$9.4	Centessa, ventyx Biosciences, verve
Amgen	$13.2	↑ 36%	ND	Dark Blue Therapeutics
sanofi	$12.8[2]	↓ (1%)	$14.5	Dynavax, vicebio, blueprint Medicines
abbvie	$9.9	↑ 21%	$4.3	capstan therapeutics, RemeGen
Boehringer Ingelheim	$9.9	NA	$0.1	Simcere
Regeneron	$8.9[2]	↑ 8%	$0.2	Tessera
Gilead	$6.8	↑ 52%	$10.4	Arcellx, Ouro Medicines, interius

Source: CapIQ and Company filings as of March 31, 2026.
Note: LOE = Loss-of-exclusivity. LOE refers to first commercially significant patent expiry. Analysis includes products with >$500M in 2025 sales and LOEs by 2031. NA = Not Applicable, ND = Not Disclosed.
(1) Includes aggregate M&A and partnership disclosed upfront deal value since 2025; excludes transactions with deal terms less than $20M.
(2) Based on 50% share of Dupixent LOE value.

William Blair Biopharma Investment Banking Team

Biopharma Investment Banking

John Sonnier
Managing Director
jsonnier@williamblair.com

Christian Hodneland, Ph.D.
Managing Director
chodneland@williamblair.com

Terence Tan
Managing Director
ttan@williamblair.com

Eason Hahm
Director
ehahm@williamblair.com

Healthcare Equity Capital Markets

Steve Maletzky
Managing Director,
Head of Capital Markets
smaletzky@williamblair.com

Rakhee Bhagat
Managing Director
rbhagat@williamblair.com

Kevin Eisele
Managing Director
keisele@williamblair.com

Ilya Blanter
Managing Director,
Head of Equity-Linked Capital Markets
iblanter@williamblair.com

Healthcare M&A Advisory

Eugene Kim
Managing Director
ekim@williamblair.com

Healthcare Sales & Trading

Rich McDonald
Managing Director
Head of Sector Trading
rmcdonald@williamblair.com

Shantha Ozgen
Managing Director
Life Sciences Sales Specialist
sozgen@williamblair.com

Healthcare Leveraged Finance

Darren Bank
Managing Director,
Head of Healthcare Leveraged Finance
dbank@williamblair.com

Disclaimer

“William Blair” is a trade name for William Blair & Company, L.L.C., William Blair Investment Management, LLC and William Blair International, Ltd. William Blair & Company, L.L.C. and William Blair Investment Management, LLC are each a Delaware company and regulated by the Securities and Exchange Commission. William Blair & Company, L.L.C. is also regulated by The Financial Industry Regulatory Authority and other principal exchanges. William Blair International, Ltd is authorized and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom. William Blair only offers products and services where it is permitted to do so. Some of these products and services are only offered to persons or institutions situated in the United States and are not offered to persons or institutions outside the United States. This material has been approved for distribution in the United Kingdom by William Blair International, Ltd. Regulated by the Financial Conduct Authority (FCA), and is directed only at, and is only made available to, persons falling within COB 3.5 and 3.6 of the FCA Handbook (being “Eligible Counterparties” and Professional Clients). This Document is not to be distributed or passed on at any “Retail Clients.” No persons other than persons to whom this document is directed should rely on it or its contents or use it as the basis to make an investment decision.

This document including, without limitation, to the statistical information within, is provided for informational purposes only. The material in this document is based, in part, on information from third-party sources that we believe are reliable, though have not been independently verified by William Blair. We do not represent that it is fully accurate or complete, and it should not be relied upon as such. The information should not be viewed as an investment, legal, or other advice, nor should it be relied on in making an investment or other decisions.